Table 1 Patients characteristics after propensity-score matching.

From: Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer

Variables

SEED-BT alone (n = 102)

SEED-BT plus EBRT (n = 102)

P

Age at radiotherapy, median (range), years

69 (50–81)

71 (49–79)

0.359

PSA at diagnosis, median (range), ng/mL

8.5 (2.6–16.7)

8.3(4.1–18.8)

0.902

Clinical stage, number (%)

  

0.322

T1c

55 (53.9)

62 (58.8)

 

T2a-c

47 (46.1)

40 (41.2)

 

Gleason grade, number (%)

  

0.809

1

17 (16.7)

19 (18.6)

 

2

31 (30.4)

27 (26.5)

 

3

54 (52.9)

56 (54.9%)

 

Positive biopsy core rate, number (%)

  

0.640

< 34%

57 (55.9)

60 (58.8)

 

34–67%

42 (41.2)

37 (36.3)

 

> 67%

3 (2.9)

5 (4.9)

 

Unfavorable intermediate risk, number (%)

75 (73.5)

79(77.4)

0.515

Neoadjuvant hormonal therapy yes, number (%)

24 (23.5)

24 (23.5)

1.000

Anti-androgen agent alone, number

1

7

 

Anti-androgen agent with GnRHa, number

20

17

 

GnRHa alone, number

3

0

 

Adjuvant hormonal therapy yes, number (%)

0 (0)

0 (0)

Follow-up, median (range), months

97 (22–153)

90 (18–153)

0.046

BED, median (range), Gy2

200.0 (138.3–281.3)

217.1 (192.2–284.1)

< 0.001

BED ≥ 200 Gy2, number (%)

51 (50.0)

96 (94.1)

< 0.001

Prostate D90, median (range), Gy

187.7 (132.2–258.4)

124.7 (97.0–180.8)

< .0001

Prostate V100, median (range), %

98.9 (84.7–100)

96.7 (87.7–99.6)

< 0.001

Prostate V150, median (range), %

70.7 (40.1–97.2)

64.9 (39.2–87.5)

< 0.001

  1. Prostate D90 indicates minimal dose received by 90% of prostate gland at 1 month on SEED-BT. Prostate V100 and V150 indicates percentage of prostate gland volume receiving 100% and 150% of the prescribed dose, respectively, at 1 month on SEED-BT.
  2. BED, biochemical effective dose; EBRT, external beam radiotherapy; GnRHa, gonadotropin-releasing hormone agonist; PSA, prostate specific antigen; SEED-BT, seed brachytherapy.